What is a contraindication for the use of Arixtra?

Arixtra, known generically as fondaparinux, is an anticoagulant that is contraindicated in patients with diminished renal function, specifically those with a creatinine clearance (CrCl) of less than 30 mL/min. This is due to the increased risk of accumulation of the drug in the body, which can lead to a higher risk of bleeding complications. The kidneys are responsible for excreting fondaparinux, and when renal function is impaired, the drug's levels can rise to potentially dangerous amounts.

In contrast, having a creatinine clearance greater than 50 mL/min is not a contraindication; in fact, fondaparinux can be safely used in patients within this clearance range or higher, as their renal function is sufficient for the drug to be appropriately cleared from the body. The age under 18 does not inherently contraindicate the use of Arixtra; however, caution should always be exercised when prescribing to younger populations, considering the specific clinical indications. Lastly, low blood pressure alone is not a specific contraindication for Arixtra, though it may warrant careful monitoring and evaluation of the patient's overall clinical status.